Icosapent ethyl for CV risk reduction: who and when?

Details & Video

Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)

Program Time: 28 minutes
Accreditation-CME Credits: This program is not accredited. Physicians may earn self-learning credits through active steps. See the Accreditation tab for more information.
Target Audience: clinical cardiologists, general internists, diabetologists, primary care physicians and pharmacists

 

View the Links & Resources tab to download the program slides and a transcript, as well as review the list of other podcast platforms where you can listen to this program.

Overview & Objectives

Icosapent ethyl for CV risk reduction: who and when?

Target Audience: clinical cardiologists, general internists, diabetologists, primary care physicians and pharmacists.

Icosapent ethyl, as shown in the REDUCE-IT study, represents the first agent to improve CV outcomes when added to statin therapy in high-risk patients with elevated triglyceride levels.  The clinical benefits of icosapent ethyl are impressive, with demonstrated safety and tolerability, thus creating a major opportunity for the prevention of CV events and mortality in Canada.

However, there are substantial complexities for clinicians to adopt icosapent ethyl in the management of high risk patients.  This podcast discusses the use of Icosapent ethyl for CV risk reduction with a focus on which patient and when this treatment should be considered. 




Accreditation

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

You will receive a Certificate of Attendance for your records if you complete the program on MD-Online as a registered user.



Faculty

Faculty

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS
Brampton, ON

Shaun Goodman
Shaun Goodman
MD, MSc, FRCPC, FACC, FAHA, FESC, FCCS
Toronto, ON

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
&
Presenter
Do serum triglycerides predict risk?
Milan Gupta
Do fish oils reduce risk?
Shaun Goodman
What are the key results from REDUCE-IT?
Milan Gupta
In which patients should we consider icosapent ethyl?
All


Sponsorship

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from HLS Therapeutics Inc.



Links & Resources

Program slides for download

Program transcript for download

 

Listen on these podcast platforms (click to access):

Anchor

Apple

Google

Spotify

Sound Cloud